Previous 10 | Next 10 |
Shares of cardiovascular drug specialist Amarin (NASDAQ: AMRN) fell by another 9.2% through the first four days of trading this week, according to data provided by S&P Global Market Intelligence . As a result, the company's stock price has now dropped by a whopping 58% so fa...
Amarin ( NASDAQ: AMRN ) on Wednesday said UK's National Institute for Health and Care Excellence (NICE) had issued its final guidance recommending the company's Vazkepa medicine for reimbursement and use across the national health service in England and Wales. Vazkepa ...
-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA ® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-tre...
Amarin saw a major price drop recently. This follows the earnings miss and the suspended guidance. While the company is making every effort, the true cure is in a sell. Amarin ( AMRN ) is back in the news again, with the latest being the mineral oil bogey being raise...
3 Tips for Buying Penny Stocks in July 2022 When it comes to buying penny stocks, there are a few things you should know in order to make the most informed decision possible. The most crucial aspect when it comes to trading penny stocks is to know what you’re buying. Itȁ...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) announced on Thursday that serum samples of patients treated with its heart disease drug icosapent ethyl (IPE) had only limited differences in certain biomarkers compared to those who received a placebo. Previous d...
-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an explo...
The shares of commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) dropped sharply on Thursday after Stat News raised concerns over the effectiveness of its heart disease therapy Vascepa. Following a new analysis, the report said that multiple experts called for cl...
HLS Therapeutics said it signed product listing agreements (PLA) with New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) for First Nations and Inuit peoples, for public reimbursement of heart drug Vascepa on their respective public prescription drug insurance...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...